Alexander Eggermont, MD, PhD, on Melanoma: Results From the EORTC 18071 Trial
2016 ESMO CongressAlexander Eggermont, MD, PhD, of Gustave Roussy, discusses final overall survival findings on ipilimumab vs placebo after complete resection of stage III melanoma. (Abstract LBA2)
Related Videos
Katja Weisel, MD, on Multiple Myeloma: Results of the CASTOR Study (German Language Version)
Katja Weisel, MD, of the University of Tübingen, discusses in German study findings on daratumumab, bortezomib, and dexamethasone vs bortezomib and dexamethasone in patients with rela...
Giorgio V. Scagliotti, MD, PhD, on ALK-Rearranged NSCLC: Results From the ASCEND-5 Trial (Italian Language Version)
Giorgio V. Scagliotti, MD, PhD, of the University of Torino, discusses in Italian study findings on ceritinib vs chemotherapy in patients with advanced ALK-rearranged non–sma...
Sian A. Pugh, MBBS, on Colorectal Cancer: Long-Term Results of the FACS Trial
Sian A. Pugh, MBBS, of Southampton University Hospital, discusses 6 to 12-year findings on the scheduled use of the CEA tumor marker and CT follow-up to detect recurrence of colorecta...
Philippe Rochigneux, MD, on Solid Tumors: Use of Chemotherapy Near the End of Life
Philippe Rochigneux, MD, of the Paoli Calmettes Institute, Marseille Cancer Center, discusses his findings on the high rates of chemotherapy used at the end of life for metastatic sol...
Jung-min Lee, MD, on Ovarian Cancer: Study Results on Checkpoint Kinase Inhibitors
Jung-min Lee, MD, of the National Cancer Institute, discusses findings of a phase II study of the cell cycle checkpoint kinase inhibitors LY2606368 and prexasertib monomesylate monohy...
